Oncopharmpod
Olaratumab, Goodbye?
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:18:06
- More information
Informações:
Synopsis
Olaratumab received accelerated approval in 2016 under the condition a phase III study would confirm its benefit. It didn't. We explore some possible explanations why a seemingly promising drug for a tough disease hasn't panned out...
